This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imaizumi, T. Articles by Takeshita, A. Search for Related Content PubMed PubMed Citation Articles by Imaizumi, T. Articles by Takeshita, A.

Hypertension, Vol 20, 54-58, Copyright © 1992 by American Heart Association

ARTICLES

Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans

T Imaizumi, S Harada, Y Hirooka, H Masaki, M Momohara and A Takeshita
Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

An orally effective, nonpeptide vasopressin V1 receptor antagonist, OPC- 21268 was produced for possible human use. We investigated the effects of OPC-21268 on the vascular effects of intra-arterially infused arginine vasopressin in human forearm vessels. The brachial artery was cannulated for drug infusions and direct measurement of arterial pressure. Forearm blood flow was measured by a strain gauge plethysmograph, and forearm vascular resistance was calculated. Arginine vasopressin was infused intra-arterially at doses of 0.02, 0.06, 0.09, 0.2, 0.6, and 1.2 ng/kg/min. The lower doses of arginine vasopressin increased, whereas the higher doses of arginine vasopressin decreased forearm vascular resistance (p less than 0.01). Intra- arterial infusion of phenylephrine at doses of 0.2, 0.4, and 2.4 micrograms/min increased forearm vascular resistance dose-dependently (p less than 0.01). OPC-21268 (50 mg for two, 100 mg for six, and 200 mg for two subjects) given orally did not alter resting arterial pressure, forearm vascular resistance, or heart rate. OPC-21268 decreased vasoconstrictor responses to arginine vasopressin at doses of 0.02 (p less than 0.02) and 0.09 (p less than 0.05) ng/kg/min and augmented vasodilator responses to arginine vasopressin at a dose of 1.2 ng/kg/min (p less than 0.01). However, the vasoconstrictor responses to phenylephrine were not altered by OPC-21268. These results demonstrated that OPC-21268 effectively and specifically antagonized the V1 receptor-mediated vasoconstriction in human forearm resistance vessels. These results suggest that OPC-21268 may be useful therapeutically to antagonize the vasoconstriction caused by arginine vasopressin in some pathological states.

This article has been cited by other articles:

				R. Weber, A. Pechere-Bertschi, D. Hayoz, V. Gerc, R. Brouard, J.-P. Lahmy, H. R. Brunner, and M. Burnier Effects of SR 49059, a New Orally Active and Specific Vasopressin V1 Receptor Antagonist, on Vasopressin-Induced Vasoconstriction in Humans Hypertension, November 1, 1997; 30(5): 1121 - 1127. [Abstract] [Full Text]

				Y. Hirata, H. Hayakawa, M. Kakoki, A. Tojo, E. Suzuki, D. Nagata, K. Kimura, A. Goto, K. Kikuchi, T. Nagano, et al. Receptor Subtype for Vasopressin-Induced Release of Nitric Oxide From Rat Kidney Hypertension, January 1, 1997; 29(1): 58 - 64. [Abstract] [Full Text]

				Y. Imai, C.-Y. Kim, J. Hashimoto, N. Minami, M. Munakata, and K. Abe Role of Vasopressin in Neurocardiogenic Responses to Hemorrhage in Conscious Rats Hypertension, January 1, 1996; 27(1): 136 - 143. [Abstract] [Full Text]

				K. Toba, Y. Ouchi, M. Akishita, K. Kozaki, M. Ishikawa, K. Nagano, M. Etoh, M. Hashimoto, Jing Liang, N. Ueda, et al. Improved Skin Blood Flow and Cutaneous Temperature in the Foot of a Patient with Arteriosclerosis Obliterans by Vasopressin V1 Antagonist (OPC21268): A Case Report Angiology, November 1, 1995; 46(11): 1027 - 1033. [Abstract] [PDF]